Pharmafile Logo
Pharmafocus logo
Advanced Search

multiple sclerosis

Showing 15 posts of 105 posts found.

Scotland flag

Cancer and MS drugs approved in Scotland

December 9, 2015
Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia

The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …

News
Biogen image

Biogen’s natalizumab fails Phase III endpoints

October 21, 2015
Biogen, multiple sclerosis

Biogen’s natalizumab has failed to achieve clinical endpoints in a late-stage study to prove the drug’s potential in patients with …

News
sativex

Almirall presents new data on cannabinoid-based MS treatment

October 9, 2015
Research and Development Almirall, multiple sclerosis

Almirall has presented new clinical evidences of Sativex, the only medicine derived from cannabinoids to treat spasticity symptoms in MS, …

News
Genentech logo

Positive late-stage results for Genentech’s ocrelizumab in different forms of MS

October 8, 2015
Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab

Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …

News
Gilenya

Novartis looks to new measure of Gilenya outcomes

October 8, 2015
Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis

Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …

News
Genzyme

Genzyme’s Lemtrada shows five-year efficacy in extended trials

October 8, 2015
Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis

Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …

News
ms_symptoms

Multiple Sclerosis treatment will be a $20bn market by 2024

October 7, 2015
Research and Development multiple sclerosis

The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion …

News
ms_early_intervention

Experts call for greater urgency in MS treatment

October 7, 2015
Research and Development multiple sclerosis

A therapeutic strategy in multiple sclerosis (MS) that aims to maximise lifelong brain health (neurological reserve) needs to be widely …

News
neuron

Neurology comes to the fore

September 7, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology

Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …

Feature
novartis

Novartis buys rights to GSK MS drug for up to $1 billion

August 21, 2015
Medical Communications, Research and Development, Sales and Marketing GlaxoSmithKline, Novartis, multiple sclerosis, ofatumumab

Novartis has added to its burgeoning multiple sclerosis portfolio with the $300 million acquisition of all outstanding rights to GlaxoSmithKline’s …

News
Celgene

Celgene to acquire Receptos in $7.2bn deal

July 15, 2015
Sales and Marketing Celgene, Crohn's, Crohn’s disease, Receptos, acquisitions, crohn's disease, mergers, multiple sclerosis, ozanimod, relapsing multiple sclerosis, ulcerative colitis

Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …

News

Biogen to build billion-dollar plant in Switzerland

July 7, 2015
Manufacturing and Production Alzherimer's disease, Biogen, Biogen IDEC, MS, Switzerland, manufacturing, multiple sclerosis

Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal with the future demand for …

News

Novartis MS drug scores positive late-stage trial result

April 21, 2015
Research and Development, Sales and Marketing MS, Novartis, fingolimod, gilenya, multiple sclerosis

People with some of the most common forms of multiple sclerosis (MS) who are treated with Gilenya are less likely …

News
Rilutek (riluzole) image

Multiple sclerosis studies underway using existing drugs

April 2, 2015
Research and Development, Sales and Marketing MS, Midamor, Prozac, Rilutek, Sanofi, amiloride, covis, fluoxetine, multiple sclerosis, riluzole

Three existing drugs that fight heart disease, depression and motor neurone disease could be used to treat multiple sclerosis (MS) …

News
Biogen Idec image

Mixed results for Biogen’s MS drug

January 9, 2015
Sales and Marketing Anti-LINGO-1, BIIB033, Biogen IDEC, MS, multiple sclerosis, plegridy

An experimental drug from Biogen Idec for the treatment of multiple sclerosis (MS) has shown a mixed bag of results …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024